{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:45:38Z","timestamp":1792079138211,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32570827"],"award-info":[{"award-number":["32570827"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515013250"],"award-info":[{"award-number":["2024A1515013250"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Provincial Key Areas Special Projects for Regular Higher Education Institutions","award":["2024ZDZX2054"],"award-info":[{"award-number":["2024ZDZX2054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-03076-8","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:44:19Z","timestamp":1784551459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the mevalonate pathway sensitizes multiple myeloma cells to bortezomib through induction of mitochondrial metabolic disruption"],"prefix":"10.1186","volume":"24","author":[{"given":"Shuya","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmeng","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2650-3816","authenticated-orcid":false,"given":"Jinheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"3076_CR1","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.blre.2025.101339","volume":"74","author":"A Mushtaq","year":"2025","unstructured":"Mushtaq A, Cheema AY, Ali HM, Shatnawi Y, Ashruf O, Ahmad EN, Lytvynova O, Munir M, Asif MA, Ahmad M, et al. Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists. Blood Rev. 2025;74:101339.","journal-title":"Blood Rev"},{"key":"3076_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","volume":"124","author":"J Wang","year":"2014","unstructured":"Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K, Menu E. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124:555\u201366.","journal-title":"Blood"},{"key":"3076_CR3","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/jha2.743","volume":"4","author":"MS Raab","year":"2023","unstructured":"Raab MS, Zamagni E, Manier S, Rodriguez-Otero P, Schjesvold F, Broijl A. Difficult-to-treat patients with relapsed\/refractory multiple myeloma: A review of clinical trial results. EJHaem. 2023;4:1117\u201331.","journal-title":"EJHaem"},{"key":"3076_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/0008-5472.CAN-23-0189","volume":"84","author":"H Zhang","year":"2024","unstructured":"Zhang H, Du Z, Tu C, Zhou X, Menu E, Wang J. Hypoxic Bone Marrow Stromal Cells Secrete miR-140-5p and miR-28-3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma. Cancer Res. 2024;84:39\u201355.","journal-title":"Cancer Res"},{"key":"3076_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12964-024-01699-3","volume":"22","author":"Y Wang","year":"2024","unstructured":"Wang Y, Vandewalle N, De Veirman K, Vanderkerken K, Menu E, De Bruyne E. Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy. Cell Commun Signal. 2024;22:320.","journal-title":"Cell Commun Signal"},{"key":"3076_CR6","first-page":"2422","volume":"110","author":"MEG Cantafio","year":"2025","unstructured":"Cantafio MEG, Valentino I, Torcasio R, Ganino L, Veneziano C, Murfone P, Mesuraca M, Perrotta I, Tallarigo F, Agosti V, et al. Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma. Haematologica. 2025;110:2422\u201335.","journal-title":"Haematologica"},{"key":"3076_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.trecan.2020.11.008","volume":"7","author":"D Juarez","year":"2021","unstructured":"Juarez D, Fruman DA. Targeting the Mevalonate Pathway in Cancer. Trends Cancer. 2021;7:525\u201340.","journal-title":"Trends Cancer"},{"key":"3076_CR8","doi-asserted-by":"publisher","first-page":"114623","DOI":"10.1016\/j.bcp.2021.114623","volume":"196","author":"MA Lasuncion","year":"2022","unstructured":"Lasuncion MA, Martinez-Botas J, Martin-Sanchez C, Busto R, Gomez-Coronado D. Cell cycle dependence on the mevalonate pathway: Role of cholesterol and non-sterol isoprenoids. Biochem Pharmacol. 2022;196:114623.","journal-title":"Biochem Pharmacol"},{"key":"3076_CR9","doi-asserted-by":"publisher","first-page":"215761","DOI":"10.1016\/j.canlet.2022.215761","volume":"542","author":"A Gobel","year":"2022","unstructured":"Gobel A, Riffel RM, Hofbauer LC, Rachner TD. The mevalonate pathway in breast cancer biology. Cancer Lett. 2022;542:215761.","journal-title":"Cancer Lett"},{"key":"3076_CR10","doi-asserted-by":"publisher","first-page":"626971","DOI":"10.3389\/fonc.2021.626971","volume":"11","author":"B Guerra","year":"2021","unstructured":"Guerra B, Recio C, Aranda-Tavio H, Guerra-Rodriguez M, Garcia-Castellano JM, Fernandez-Perez L. The Mevalonate Pathway, a Metabolic Target in Cancer Therapy. Front Oncol. 2021;11:626971.","journal-title":"Front Oncol"},{"key":"3076_CR11","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.62347\/CCCT1933","volume":"15","author":"H Teng","year":"2025","unstructured":"Teng H, Wang F, Liu H, Zhang X. Cholesterol metabolism reprogramming in multiple myeloma: examining its specificity and impact on the immune microenvironment. Am J Cancer Res. 2025;15:2004\u201321.","journal-title":"Am J Cancer Res"},{"key":"3076_CR12","doi-asserted-by":"publisher","first-page":"e2408373","DOI":"10.1002\/advs.202408373","volume":"12","author":"D Zhan","year":"2025","unstructured":"Zhan D, Du Z, Zhang S, Huang J, Zhang J, Zhang H, Liu Z, Menu E, Wang J. Targeting Caveolin-1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell-Mediated Immunotherapy. Adv Sci (Weinh). 2025;12:e2408373.","journal-title":"Adv Sci (Weinh)"},{"key":"3076_CR13","doi-asserted-by":"publisher","first-page":"111213","DOI":"10.1016\/j.cellsig.2024.111213","volume":"120","author":"FS Hosseini","year":"2024","unstructured":"Hosseini FS, Ahmadi A, Kesharwani P, Hosseini H, Sahebkar A. Regulatory effects of statins on Akt signaling for prevention of cancers. Cell Signal. 2024;120:111213.","journal-title":"Cell Signal"},{"key":"3076_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","volume":"40","author":"W Jiang","year":"2021","unstructured":"Jiang W, Hu JW, He XR, Jin WL, He XY. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021;40:241.","journal-title":"J Exp Clin Cancer Res"},{"key":"3076_CR15","doi-asserted-by":"publisher","first-page":"E328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:E328\u201346.","journal-title":"Lancet Oncol"},{"key":"3076_CR16","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"3076_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"3076_CR18","doi-asserted-by":"crossref","unstructured":"Nicolini A, Ferrari P. Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy. Front Immunol. 2024;15:1353787.","DOI":"10.3389\/fimmu.2024.1353787"},{"key":"3076_CR19","doi-asserted-by":"crossref","unstructured":"Criscuolo D, Avolio R, Calice G, Laezza C, Paladino S, Navarra G, Maddalena F, Crispo F, Pagano C, Bifulco M et al. Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer. Cells, 2020;9:828.","DOI":"10.3390\/cells9040828"},{"key":"3076_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","volume":"2","author":"BL Huang","year":"2020","unstructured":"Huang BL, Song BL, Xu CQ. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metabolism. 2020;2:132\u201341.","journal-title":"Nat Metabolism"},{"key":"3076_CR21","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1007\/s10238-023-01174-2","volume":"23","author":"R Torcasio","year":"2023","unstructured":"Torcasio R, Gallo Cantafio ME, Ikeda RK, Ganino L, Viglietto G, Amodio N. Lipid metabolic vulnerabilities of multiple myeloma. Clin Exp Med. 2023;23:3373\u201390.","journal-title":"Clin Exp Med"},{"key":"3076_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1742-4658.2009.07366.x","volume":"277","author":"S Cagnol","year":"2010","unstructured":"Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death\u2013apoptosis, autophagy and senescence. FEBS J. 2010;277:2\u201321.","journal-title":"FEBS J"},{"key":"3076_CR23","doi-asserted-by":"publisher","first-page":"108282","DOI":"10.1016\/j.pharmthera.2022.108282","volume":"238","author":"A Tajbakhsh","year":"2022","unstructured":"Tajbakhsh A, Gheibihayat SM, Askari H, Savardashtaki A, Pirro M, Johnston TP, Sahebkar A. Statin-regulated phagocytosis and efferocytosis in physiological and pathological conditions. Pharmacol Ther. 2022;238:108282.","journal-title":"Pharmacol Ther"},{"key":"3076_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.phrs.2014.11.006","volume":"91","author":"S Afshordel","year":"2015","unstructured":"Afshordel S, Kern B, Clasohm J, Konig H, Priester M, Weissenberger J, Kogel D, Eckert GP. Lovastatin and perillyl alcohol inhibit glioma cell invasion, migration, and proliferation\u2013impact of Ras-\/Rho-prenylation. Pharmacol Res. 2015;91:69\u201377.","journal-title":"Pharmacol Res"},{"key":"3076_CR25","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1126\/science.adk1785","volume":"381","author":"A Pouikli","year":"2023","unstructured":"Pouikli A, Frezza C. Metabolic control of antitumor immunity. Science. 2023;381:1287\u20138.","journal-title":"Science"},{"key":"3076_CR26","doi-asserted-by":"crossref","unstructured":"Li S, Zhang Y, Tong H, Sun HZ, Liao H, Li QF, Ma XL. Metabolic regulation of immunity in the tumor microenvironment. Cell Rep. 2025;44:116463.","DOI":"10.1016\/j.celrep.2025.116463"},{"key":"3076_CR27","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.it.2021.09.002","volume":"42","author":"LFS Patterson","year":"2021","unstructured":"Patterson LFS, Vardhana SA. Metabolic regulation of the cancer-immunity cycle. Trends Immunol. 2021;42:975\u201393.","journal-title":"Trends Immunol"},{"key":"3076_CR28","doi-asserted-by":"publisher","first-page":"116738","DOI":"10.1016\/j.biopha.2024.116738","volume":"175","author":"X Li","year":"2024","unstructured":"Li X, Zhou J, Ling Y, Tan Y, Zhang J, Wang X, Li F, Jiang S, Zhang S, Yu K, Han Y. Matrine induces autophagic cell death by triggering ROS\/AMPK\/mTOR axis and apoptosis in multiple myeloma. Biomed Pharmacother. 2024;175:116738.","journal-title":"Biomed Pharmacother"},{"key":"3076_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","volume":"19","author":"P Robak","year":"2019","unstructured":"Robak P, Robak T. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs R D. 2019;19:73\u201392.","journal-title":"Drugs R D"},{"key":"3076_CR30","doi-asserted-by":"publisher","first-page":"e6614","DOI":"10.1002\/ccr3.6614","volume":"10","author":"H Kimura","year":"2022","unstructured":"Kimura H, Furukawa M, Mori H, Shiga Y, Asai J, Satoh K, Kai T. Development of multiple myeloma after 15 years of treatment for polycythemia vera and successful treatment using bortezomib: A case report. Clin Case Rep. 2022;10:e6614.","journal-title":"Clin Case Rep"},{"key":"3076_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41408-023-00937-0","volume":"13","author":"R Banerjee","year":"2023","unstructured":"Banerjee R, Wang B, Anderson LD Jr., McCaughan G, Mehra N, Cowan AJ, Rajkumar SV, Kaur G. Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians. Blood Cancer J. 2023;13:162.","journal-title":"Blood Cancer J"},{"key":"3076_CR32","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"3076_CR33","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1111\/cas.14178","volume":"110","author":"K Maekawa","year":"2019","unstructured":"Maekawa K, Ri M, Nakajima M, Sekine A, Ueda R, Tohkin M, Miyata N, Saito Y, Iida S. Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma. Cancer Sci. 2019;110:3267\u201374.","journal-title":"Cancer Sci"},{"key":"3076_CR34","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1007\/s12094-025-04162-y","volume":"28","author":"I El Sayed","year":"2026","unstructured":"El Sayed I. Antitumoral and cardioprotective roles of statins: underlying types, mechanisms, current evidence, and emerging perspectives. Clin Transl Oncol. 2026;28:2580\u201392.","journal-title":"Clin Transl Oncol"},{"key":"3076_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cllc.2024.12.008","volume":"26","author":"MT Marrone","year":"2025","unstructured":"Marrone MT, Reuss JE, Crawford A, Neelon B, Liu JO, Brahmer JR, Platz EA. Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer. Clin Lung Cancer. 2025;26:201\u20139.","journal-title":"Clin Lung Cancer"},{"key":"3076_CR36","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1002\/cam4.2151","volume":"8","author":"Y Li","year":"2019","unstructured":"Li Y, He XK, Ding YE, Chen HY, Sun LM. Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta-analysis. Cancer Med. 2019;8:3305\u201313.","journal-title":"Cancer Med"},{"key":"3076_CR37","doi-asserted-by":"crossref","unstructured":"Vos WG, Lutgens E, Seijkens TTP. Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer? J Immunother Cancer. 2022;10:e005611.","DOI":"10.1136\/jitc-2022-005611"},{"key":"3076_CR38","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.1016\/j.clml.2020.02.011","volume":"20","author":"B Ponvilawan","year":"2020","unstructured":"Ponvilawan B, Charoenngam N, Rittiphairoj T, Ungprasert P. Receipt of Statins Is Associated With Lower Risk of Multiple Myeloma: Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2020;20:e399\u2013413.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3076_CR39","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1016\/j.clml.2020.07.003","volume":"20","author":"A Afzal","year":"2020","unstructured":"Afzal A, Fiala MA, Gage BF, Wildes TM, Sanfilippo K. Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study. Clin Lymphoma Myeloma Leuk. 2020;20:e937\u201343.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3076_CR40","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ajh.25778","volume":"95","author":"E Branvall","year":"2020","unstructured":"Branvall E, Ekberg S, Eloranta S, Wasterlid T, Birmann BM, Smedby KE. Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients. Am J Hematol. 2020;95:652\u201361.","journal-title":"Am J Hematol"},{"key":"3076_CR41","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1200\/JCO.2016.68.3482","volume":"34","author":"KM Sanfilippo","year":"2016","unstructured":"Sanfilippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, Gumbel J, Blue B, O\u2019Brian K, Carson KR. Statins Are Associated With Reduced Mortality in Multiple Myeloma. J Clin Oncol. 2016;34:4008\u201314.","journal-title":"J Clin Oncol"},{"key":"3076_CR42","doi-asserted-by":"crossref","unstructured":"He C, Xu K, Zhu XY, Dunphy PS, Gudenas B, Lin WW, Twarog N, Hover LD, Kwon CH, Kasper LH et al. Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. Nat Commun. 2021;12:4089.","DOI":"10.1038\/s41467-021-24168-8"},{"key":"3076_CR43","first-page":"0447","volume":"7","author":"H Xiao","year":"2024","unstructured":"Xiao H, Li W, Qin Y, Lin Z, Qian C, Wu M, Xia Y, Bai J, Geng D. Crosstalk between Lipid Metabolism and Bone Homeostasis: Exploring Intricate Signaling Relationships. Res (Wash D C). 2024;7:0447.","journal-title":"Res (Wash D C)"},{"key":"3076_CR44","doi-asserted-by":"crossref","unstructured":"Wang Y, Lan TW, Zhou C, Zhang QY, Liu P. LRP8-dependent cholesterol metabolism modulates mTORC1 signaling and apoptotic pathways in multiple myeloma. Cell Death Dis. 2025;16:263.","DOI":"10.1038\/s41419-025-07625-w"},{"key":"3076_CR45","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.scib.2024.04.044","volume":"69","author":"M Huang","year":"2024","unstructured":"Huang M, Zhou JX, Li XX, Liu R, Jiang YZ, Chen KX, Jiao YR, Yin X, Liu L, Sun YC, et al. Mechanical protein polycystin-1 directly regulates osteoclastogenesis and bone resorption. Sci Bull. 2024;69:1964\u201379.","journal-title":"Sci Bull"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-03076-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:03:26Z","timestamp":1792076606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-03076-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3076"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-03076-8","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee of Guangzhou Medical University.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"555"}}